MYCobiome analysis in atopic dermatitis with head and neck involvement
Topic / Pathology
- observational
Objectives
Perform mycobiome analysis in the head and neck regions of 30 adults with atopic dermatitis compared with 15 healthy controls.
Patients will be classified into 2 subgroups according to the topography and body surface area affected by AD;
Group 1: generalized AD defined by an AD skin lesion affecting more or less 50% of the total body surface, with head and neck involvement (15 patients)
Group 2: DA of the head and neck defined by DA affecting at least 80% of the head and neck with or without DA outside the head and neck but <20% of the total body surface area. (15 patients)
Group 3: Healthy controls without chronic skin disease. Healthy controls will be recruited from non-atopic patients investigated in our departments for drug allergy after resolution of acute events (15 healthy controls).
https://clinicaltrials.gov/study/NCT06455891?term=NCT06455891&ran
Sponsor
APHP
Investigator
Pr Angèle Soria
Critères d'inclusion
- Age between 18 and 65 years;
- Male or female;
- The diagnosis of atopic dermatitis (AD) is defined according to the criteria of UK Working Party with at least 3 of the following 5 criteria are present; history of flexural involvement, history of a dry skin, onset under the age of 2, personal history of asthma or allergic rhinitis, history of a pruritic skin condition, and visible flexural dermatitis.
- Generalized AD defined by AD involved ≥50% of total body surface area with head and neck involvement. Or HNAD defined by AD involving at least 80% of the head and neck area with or without AD involvement outside the head and neck area but <20% of total body surface area.
- With topical anti-inflammatory treatments for AD (including; topical steroids and/or topical tacrolimus)
- Free, informed and written consent, signed by the patient and the investigator before any examination required by the trial;
- Affiliation to social security scheme (beneficiary or assignee)
- Healthy control are the same age and sex..
Critères de non-inclusion
- Systemic or local antifungal therapy within 2 months before entry and during the study
- Systemic treatments for AD; including: ciclosporine, dupilumab and others AD biologics, methotrexate, JAK-inhibitors
- Generalized AD without head and neck involvement
- AD involved less than 50% of total body surface
- Head and neck AD with less than 80% of the head and neck area involved
- Head and neck AD with more than 20% of AD involvement outside the head and neck area
- Current participation in another biomedical research
- Patient with a measure of legal protection
- Psychiatric illness or any other concomitant chronic illness or addiction that could be interfere with the ability to meet the requirements of the protocol or provide informed consen
Status
Ongoing
